What is the specific difference between Zoltuximab and Veroximab?

In terms of drug naming, zolbetuximab and Vyloy essentially point to the same anti-CLDN18.2 monoclonal antibody, but there are certain differences in clinical use and market presentation. Zotuximab is the international nonproprietary name (INN) of the drug, which is usually used in academic literature, clinical trials and international guidelines; while Vyloy is the trade name of the drug in specific markets to facilitate identification by patients and doctors, especially in drug prescription and sales.

The drug ingredients, molecular structures and mechanisms of action of the two drugs are exactly the same, and both exert anti-tumor effects by targeting CLDN18.2. Its core functions include inducing antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), targeting patients with gastric cancer and gastroesophageal junction adenocarcinoma with high expression of CLDN18.2. The therapeutic efficacy, pharmacokinetics and safety data are consistent for both zotuximab and Vyloy, and have shown similar efficacy and tolerability in clinical trials.

The difference is mainly reflected in the market and regulatory levels. Zotuximab as a generic name is more convenient for international academic exchanges and drug registration, while Vyloy is a brand name in specific countries and regions after commercialization to facilitate patient identification and commercial promotion. In addition, the product packaging, dosage specifications and instructions of Vyloy may be slightly different according to the registration requirements in different regions, such as the content of each vial or bottle, dilution method and administration instructions, but the pharmacological essence remains unchanged.

In short,Zolbetuximab and Vyloy are two named forms of the same drug. The former emphasizes academics and versatility, while the latter emphasizes market and brand identity. In clinical application, doctors and patients should pay attention to the indications, dosage, administration methods and monitoring measures of the drug rather than naming differences, so as to ensure a safe and effective treatment experience.

Reference materials:https://www.astellas.com/en/news/29401